NCT05527743

Brief Summary

Carpal Tunnel Syndrome (CTS) is the most common peripheral neuropathy due to entrapment, caused by compression of the median nerve as it passes under the transverse carpal ligament at the wrist. The prevalence of CTS is between 5% and 20% in the general population, according to the criteria used. It stands at 10% when following the criteria established by the National Institute for Occupational Safety and Health. Within the prevalence, 1% are men and 7% women, with an incidence per year of 105 cases per 100,000 people. In 2019, the external consultant "statista" indicated that approximately 924,000 cases of CTS were registered in Spain. CTS generates large saturations in rehabilitation in primary care and in preoperative lists, for example, in 2008 there were 4,109 hospital admissions with a rate of 0.18 hospital discharges per thousand. Risk factors for the development of CTS include female sex, older age, diabetes, menopause, hypothyroidism, obesity and pregnancy. Smoking appears to be a risk factor in the development of CTS. As well as wrist hyperflexion and hyperextension movements. The number of risk factors present progressively increases the prevalence of CTS. CTS is characterized by the presence of neuropathic pain, nocturnal paresthesias and dysesthesia. It can be combined with loss of strength and atrophy of the tenar muscles. Therefore, the most severe cases produce very notable physical, psychological and economic consequences. For example, in the United States, CTS generates an annual primary care expenditure of $2 billion. Currently, the most recent clinical guidelines recommend the use of orthoses, exercises and manual therapy in the management of CTS, although there is no consensus on the most effective option. On the other hand, surgery is one of the most used therapeutic options. However, there is a great collapse of the health system and the waiting list for the intervention and it can take a long time. The conservative therapeutic options used to date focus on the local approach to CTS at the wrist, and a recent systematic review has shown a high rate of surgical need (around 60%) at 3-year follow-up. This need for surgery may be reduced in the long term to 15% if the conservative approach includes maneuvers focused on desensitization of the central nervous system, performing an approach to the entire upper extremity. Current evidence suggests that CTS is a complex disorder, which presents sensitization mechanisms of the nervous system, and not only a peripheral nerve compression at the carpal tunnel level. Therefore, approaches and therapies with a central effect are hypothesized to be of future interest, in accordance with current nociceptive theories of CTS. In the field of physiotherapy, novel techniques have been developed in recent years, such as ultrasound-guided percutaneous musculoskeletal electrolysis and ultrasound-guided percutaneous neuromodulation, in which different types of electrical current are applied through solid needles. Different mechanisms of action have been associated with these invasive techniques, such as a potential effect on the activation of the descending pain inhibitory system pathways, the reduction of evoked motor potentials and an increase in intracortical inhibition, suggesting benefits in patients with central sensitization. Invasive electrolysis and neuromodulation techniques have been applied in other studies at the nerve level, especially in the sciatic nerve at the piriformis and hamstrings level, in the popliteal fossa and in the foot. However, there is no study performed in patients with CTS. To date, there is no clear consensus on the therapeutic approach to CTS, and the application of these invasive physiotherapy techniques is a novel approach that encompasses the local effect of treatment by means of local ultrasound-guided insertion of the needle in the carpal tunnel and the central neurophysiological effect produced by the current when it is applied. Taking into account the good empirical results found in private clinics and the precedents of studies carried out in other nerves, this treatment approach for outpatient application in primary care centers could relieve the demand for hospital care for patients referred for surgical treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 2, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

April 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

September 2, 2022

Status Verified

August 1, 2022

Enrollment Period

1 year

First QC Date

August 26, 2022

Last Update Submit

August 31, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in Present Pain Intensity (NPRS 0-10)

    The intensity of hand pain will be recorded, using an 11-point numerical scale (NPRS) (0=no pain, 10=maximum pain). They will be asked for current pain. Because there is no value that determines the minimum clinically relevant difference in hand pain, a 2-point change, or 30% change, will be considered clinically relevant (38).

    Baseline; 1 month follow-up; 6 month follow-up

  • Change in Pain Intensity in the previous week (NPRS 0-10)

    The intensity of hand pain will be recorded, using an 11-point numerical scale (NPRS) (0=no pain, 10=maximum pain). They will be asked for the worst pain experienced in the previous week. Because there is no value that determines the minimum clinically relevant difference in hand pain, a 2-point change, or 30% change, will be considered clinically relevant (38).

    Baseline; 1 month follow-up; 6 month follow-up

Secondary Outcomes (8)

  • Change in Neurophysiological study (m/s)

    Baseline; 1 month follow-up; 6 month follow-up

  • Change in BOSTON questionnaire

    Baseline; 1 month follow-up; 6 month follow-up

  • Change in Global rating of change scale

    Baseline; 1 month follow-up; 6 month follow-up

  • Change in Katz Diagram

    Baseline; 1 month follow-up; 6 month follow-up

  • Change in Grip strength (Newtons)

    Baseline; 1 month follow-up; 6 month follow-up

  • +3 more secondary outcomes

Study Arms (2)

Invasive Physiotherapy

EXPERIMENTAL
Other: Invasive Physiotherapy

Sham Group

PLACEBO COMPARATOR
Other: Sham

Interventions

They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.

Invasive Physiotherapy
ShamOTHER

The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37). Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research.

Sham Group

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age equal or superior to 18 years old.
  • Have a medical diagnosis of CTS, by a specialist of the Neurophysiology Service with confirmation of neurophysiological study, in any of its stages: mild, moderate or severe.
  • Have access and be able (or have help) to use an online platform to conduct "meetings" with the health professional.
  • Read the informed consent form and understand the objectives and conduct of the study.

You may not qualify if:

  • Be pending compensation or litigation for health problems.
  • Receiving physiotherapy treatment in the region in the month prior to the study.
  • Present severe diseases that may be related to the clinical results: malignancy or history of cancer, tumors or fractures in the region to be treated, blood dyscrasia, severe trauma in the previous 3 months, surgery in the region in the previous 12 months.
  • To present contraindications to the therapeutic approach such as Belanophobia (33).
  • Subjects who have received any of the procedures under study (percutaneous neuromodulation or percutaneous electrolysis technique).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universitat Internacional de Catalunya

Sant Cugat del Vallès, Barcelona, 08195, Spain

Location

Related Publications (1)

  • Borrella-Andres S, Rodriguez-Sanz J, Lopez-de-Celis C, Marques Garcia I, Bueno-Gracia E, Rodriguez-Mena D, Malo-Urries M. Effect of ultrasound-guided percutaneous electrolysis and nerve stimulation on pain and function in carpal tunnel syndrome: A randomized clinical trial. Pain Med. 2025 Dec 4:pnaf170. doi: 10.1093/pm/pnaf170. Online ahead of print.

MeSH Terms

Conditions

Carpal Tunnel Syndrome

Interventions

salicylhydroxamic acid

Condition Hierarchy (Ancestors)

Median NeuropathyMononeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNerve Compression SyndromesCumulative Trauma DisordersSprains and StrainsWounds and Injuries

Central Study Contacts

Jacobo Rodríguez-Sanz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 26, 2022

First Posted

September 2, 2022

Study Start

April 1, 2023

Primary Completion

April 1, 2024

Study Completion

December 1, 2024

Last Updated

September 2, 2022

Record last verified: 2022-08

Locations